Skip to main content

09-29-2020 | EASD 2020 | Conference coverage | Article

EMPEROR-Reduced: Time for a change in the HF guidelines?

Miles Fisher comments on the findings from the EMPEROR-Reduced trial, which demonstrated cardioprotective effects of empagliflozin irrespective of diabetes in patients with heart failure, and discusses whether SGLT2 inhibitors should be incorporated into heart failure treatment guidelines (5:08).

Read the transcript

Related topics

Virtual EASD Annual Meeting 2020 coverage

Catch-up with news stories and expert commentary.

Image Credits